Bromantane Research Guide: Actoprotector & Dopamine Pathways

What Is Bromantane?

Bromantane (also written Bromantan; brand name Ladasten; developmental codes ADK-709 / N-71) is a synthetic small molecule built on the adamantane cage. Chemically it is N-(4-bromophenyl)adamantan-2-amine — an adamantan-2-yl group joined to a para-bromoaniline. It was developed in the 1980s at the Zakusov Institute of Pharmacology in the former USSR and is classified in the Russian pharmacological literature as an actoprotector: a synthetic adaptogen described as raising resistance to physical and mental load without increasing oxygen consumption or heat production. It is also characterized there as an atypical, mild CNS stimulant with anxiolytic properties.

Structurally, bromantane belongs to the same adamantane family as amantadine, memantine and rimantadine, but the bromophenyl-amino substituent distinguishes it from those analogs — and, as the next section discusses, it appears to act through a different mechanism. The identity data below come from secondary references cross-checked against the primary pharmacology literature; the CAS number and molecular weight are consistent across sources.

Mechanism of Action: What the Research Shows

Bromantane's defining feature is what it does not do. Unlike amphetamine-type stimulants, the published work reports that it does not act primarily on the dopamine transporter as a releaser or reuptake blocker. Instead it appears to operate through an indirect, comparatively slow genomic mechanism: in the cited preclinical work it upregulates expression of tyrosine hydroxylase (TH) — the rate-limiting enzyme of dopamine synthesis — and of aromatic L-amino-acid decarboxylase (AADC/AAAD), increasing de novo dopamine biosynthesis and the available pool of dopamine for release.

In rats, this effect is reported to be regionally differential across the ventral tegmental area, nucleus accumbens, hypothalamus, striatum and hippocampus, with TH regulated at both the mRNA and protein level alongside changes in L-DOPA and dopamine content (Mikhaylova 2007, Neuropharmacology). Separately, in vivo microdialysis showed a pronounced and unusually prolonged (~8 hour) rise in extracellular striatal dopamine after a single dose (Grekhova 1995) — a time course more consistent with synthesis-driven activation than with fast transporter blockade.

Reported Downstream and Secondary Effects

Beyond dopamine biosynthesis, animal and ex-vivo work attributes a set of secondary effects to bromantane. These are preclinical and not clinically confirmed:

• Hippocampal synaptic plasticity — reported conversion of short-term potentiation into a long-lasting form, dependent on protein synthesis and D1-type dopamine receptors.
• Neurotrophin expression — increased BDNF and NGF/GDNF reported in animal models.
• GABAergic modulation and possible serotonergic involvement.
• Anti-inflammatory effects — lowering of pro-inflammatory cytokines such as IL-6 and IL-17 in some preparations.

An important honesty note: the precise upstream molecular trigger for the TH/AADC upregulation is not definitively established. Proposed signalling routes (for example PKA/PKC, HDAC inhibition, or sigma-1 involvement shared with other adamantanes) remain unconfirmed, and the mechanism should be regarded as coherent but incomplete. Popular framing online about "permanent dopamine upregulation" is extrapolation beyond the short-duration animal data and should be treated as a hypothesis, not an established finding.

What the Research Literature Reports

Bromantane's evidence base is genuinely interesting because it sits in a middle ground: it has more human data than most "research compounds," but that data is geographically and institutionally narrow. The findings below are reported for context on what the published literature has observed in its original study populations; none of it is a use indication for research-grade material.

The Central Mechanistic Paper

The key preclinical study is Mikhaylova et al., Neuropharmacology, 2007 (PMID 17854844). A single oral dose of ladasten (50 mg/kg) in rats differentially regulated tyrosine hydroxylase mRNA and protein and altered L-DOPA/dopamine content across the VTA, nucleus accumbens, hypothalamus, striatum and hippocampus, and converted short-term hippocampal potentiation into a long-lasting, protein-synthesis- and D1-dopamine-dependent form. This is the paper that links bromantane to TH/AADC-driven dopamine biosynthesis and plasticity. Notably, it was co-authored from a German neurobiology institute, so the core dopamine-biosynthesis story is not a single-lab artifact.

Striatal Dopamine Time Course

Grekhova et al., 1995 (Bulletin of Experimental Biology and Medicine; PMID 7795203) used in vivo microdialysis in freely moving rats and reported a pronounced, prolonged (~8 hour) increase in dopamine release and metabolism in the dorsal striatum after a single dose — consistent with synthesis-driven rather than transporter-blocking activation. A companion pharmacokinetic/pharmacodynamic paper (Morozov et al., 1995, Eksperimental'naya i Klinicheskaya Farmakologiya; PMID 7795204) correlated plasma levels with the delayed-onset, long-duration effect profile expected of a synthesis-upregulating agent.

The Human Clinical Literature

There is real human data on asthenic disorders. A pilot trial (Siuniakov et al., Eksp Klin Farmakol, 2006; PMID 16995430) in patients with psychogenic asthenic disorder reported a combined stimulant-plus-anxiolytic profile, with the stimulant action predominating on single dosing. The largest report is a multicenter Russian study of 728 evaluable patients with psychoautonomic/asthenic syndrome (Voznesenskaia et al., Zh Nevrol Psikhiatr Im S S Korsakova, 2010; PMID 21322821), in which ladasten 50–100 mg/day over 28 days was associated with responder rates of 76.0% (CGI-S) and 90.8% (CGI-I), onset by day 3, and benefit persisting roughly a month after withdrawal, with adverse events in about 3% and no serious adverse events reported.

Handling & Solution Storage for Research

For this listing, bromantane is supplied as a solution in a 10 mL bottle (Research Use Only). Because it ships pre-formulated, no reconstitution is required. Bromantane is a small, fairly lipophilic adamantane; the free base has low aqueous solubility and is typically dissolved in a non-aqueous or co-solvent vehicle (for example an alcohol/glycol or oil carrier). The exact solvent and concentration are product-specific and should be read off the Certificate of Analysis (COA) before any bench work.

• Store refrigerated. On receipt, keep the bottle refrigerated (typically 2–8 °C), tightly capped and protected from light.
• Match the diluent to the vehicle. If a working dilution is needed, match the diluent to the supplied solvent to avoid precipitation — solvent compatibility depends on what the stock is dissolved in.
• Equilibrate before opening. Allow the bottle to reach room temperature before opening to reduce condensation, and minimize repeated warm/cool cycles.
• Limit light and heat exposure. Aliquot if frequent access is expected, to limit oxidation of the stock and repeated thermal cycling.
• Verify against the COA. Confirm identity, purity and concentration (mg/mL) against the supplied COA — the exact solvent, concentration and stability window are product-specific and should not be assumed.

Bromantane vs Amantadine, Memantine & Amphetamine

Researchers most often search bromantane against three reference points. The contrasts below are mechanistic framing, not therapeutic comparison.

Within the Adamantane Family

Bromantane shares the adamantane cage with amantadine and memantine (and rimantadine, adapromine). Those analogs are associated with dopaminergic/anti-Parkinsonian activity, NMDA-receptor antagonism, and proposed sigma-1 activity. The question researchers probe is whether bromantane's CNS effects share that adamantane sigma-1/dopaminergic mechanism or are distinct — and the available evidence points toward a distinct, synthesis-upregulating action (TH/AADC) rather than the reuptake/NMDA/sigma profile of its cousins.

Versus Amphetamine and Classic Stimulants

The headline contrast is synthesis upregulation versus direct transporter action. Where amphetamine drives dopamine release and blocks reuptake at the transporter for a fast, sharp effect, the bromantane literature describes a slower-onset, longer-acting profile driven by increased biosynthesis. The preclinical reports also describe comparatively lower peripheral sympathomimetic signalling and lower abuse-liability framing — though a clean, modern human safety dataset outside Russia is lacking, so this should be read as the reported profile, not a settled safety claim.

Other Adaptogens and Co-Searched Compounds

Bromantane is also compared with other actoprotectors/adaptogens such as bemethyl (bemitil) for endurance and anti-fatigue research, and with general anti-asthenia and nootropic agents. It sits in the same "Russian-origin neuro research compound" cluster as Selank and similar peptides, which is why those names are frequently co-searched.

Evaluating Research-Grade Bromantane Supply

For reproducible work, the supply chain matters as much as the molecule — arguably more for a solution product, where concentration and solvent are everything. When sourcing bromantane for research, look for:

1. A Batch-Specific Third-Party COA

A legitimate vendor provides a Certificate of Analysis for each lot, ideally generated by an independent lab. For a small molecule like bromantane, the COA should report:

• HPLC purity — confirming the material is the intended compound at high purity.
• Mass-spec confirmation — verifying the measured mass matches the expected ~306 g/mol, which is how you confirm you actually received N-(4-bromophenyl)adamantan-2-amine and not a mislabeled or impure batch.
• Solvent and concentration (mg/mL) for a solution product, plus a batch/lot number and a recent test date linking the COA to your specific bottle.

Elytra Labs publishes batch-specific third-party COAs for the research compounds we ship. Browse our current COA library → and see our guide to reading a COA for how to interpret the chromatogram and mass-spec data.

2. Solution Discipline and Documentation

Because this is a solution rather than a lyophilized powder, the vendor should document the vehicle and the concentration, and the product should arrive refrigerated and protected from light. A vendor that states the solvent and mg/mL on the COA — rather than leaving you to guess — is doing real quality control.

Frequently Asked Research Questions

What is bromantane and what does "actoprotector" mean?

Bromantane (brand name Ladasten) is a synthetic adamantane-derived compound developed in the 1980s at the Zakusov Institute of Pharmacology in the former USSR. "Actoprotector" is the Russian pharmacological term for a synthetic adaptogen said to raise resistance to physical and mental load without increasing oxygen consumption or heat production. Chemically it is N-(4-bromophenyl)adamantan-2-amine (C₁₆H₂₀BrN, MW ~306.24, CAS 87913-26-6).

How does bromantane affect dopamine if it isn't a reuptake blocker?

The published preclinical work reports an indirect mechanism: rather than blocking the dopamine transporter like amphetamine, bromantane upregulates the dopamine-synthesis enzymes tyrosine hydroxylase (TH) and aromatic L-amino-acid decarboxylase (AADC), increasing de novo dopamine biosynthesis (Mikhaylova 2007, Neuropharmacology, PMID 17854844). Rat microdialysis showed a prolonged ~8-hour rise in striatal dopamine after a single dose (Grekhova 1995, PMID 7795203).

Does bromantane "permanently" increase dopamine?

That claim is an extrapolation beyond the data. The studies showing TH/AADC upregulation are short-duration animal experiments; they do not establish permanent or lasting changes in human subjects. The "permanent upregulation" framing common online should be treated as a hypothesis, not an established finding.

How is bromantane different from amantadine and memantine?

All three are built on the adamantane cage, but they behave differently. Amantadine and memantine are associated with dopaminergic/anti-Parkinsonian activity, NMDA-receptor antagonism and proposed sigma-1 activity, whereas the available evidence for bromantane points to a distinct synthesis-upregulating (TH/AADC) action rather than reuptake or NMDA effects.

Is bromantane banned in sport, and what is "research-grade"?

Bromantane is a WADA-prohibited substance, banned in 1997 after Russian athletes tested positive at the 1996 Atlanta Olympics — the origin of its public notoriety. (The historical "masking agent" label is contested and best described as early WADA framing rather than settled fact.) "Research-grade" means the compound is intended for laboratory in vitro and animal-model investigation and is accompanied by analytical documentation (purity, mass spec, batch records). It is not pharmaceutical- or human-grade and is not approved for human or veterinary use.